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Abstract
Background: The importance of various inflammatory cytokines in maintaining tumor cell growth
and viability is well established. Increased expression of the proinflammatory cytokine macrophage
migration inhibitory factor (MIF) has previously been associated with various types of
adenocarcinoma.
Methods: MIF IHC was used to localize MIF in human bladder tissue. ELISA and Western blot
analysis determined the synthesis and secretion of MIF by human bladder transitional cell carcinoma
cells. The effects of MIF inhibitors (high molecular weight hyaluronate (HA), anti-MIF antibody or
MIF anti-sense) on cell growth and cytokine expression were analyzed.
Results: Human bladder cancer cells (HT-1376) secrete detectable amounts of MIF protein.
Treatment with HA, anti-MIF antibody and MIF anti-sense reduced HT-1376 cell proliferation, MIF
protein secretion, MIF gene expression and secreted inflammatory cytokines. Our evidence
suggests MIF interacts with the invariant chain, CD74 and the major cell surface receptor for HA,
CD44.
Conclusions: This study is the first to report MIF expression in the human bladder and these
findings support a role for MIF in tumor cell proliferation. Since MIF participates in the inflammatory
response and bladder cancer is associated with chronic inflammatory conditions, these new findings
suggest that neutralizing bladder tumor MIF may serve as a novel therapeutic treatment for bladder
carcinoma.
Background
According to 2003 estimates, urinary bladder cancer will
be diagnosed in 57,400 Americans and will result in
12,500 deaths [1]. Of these new cases, 80 to 90% will orig-
inally present as tumors of the epithelium or submucosa,
with the majority being transitional cell carcinomas [2,3].
Transurethral resection of bladder tumor remains the ini-
tial line of defense in treatment of superficial bladder can-
cer. However, this treatment is hardly adequate as the
recurrence rate in treated patients approaches 50 to 70%
and 5 to 40% of recurrent cancers progress [2,4]. In an
attempt to curb the reoccurrence rate, a variety of immu-
notherapies and chemotherapies have been devised, with
the most common being intravesical bacillus Calmette-
Guerin [4]. The high rate of mortality associated with
invasive urinary bladder cancer and the high incidence of
reoccurrence after treatment demonstrate the need for a
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better understanding of bladder cancer and new therapeu-
tic agents for treatment.
Chronic inflammation is an established risk factor for the
development of bladder cancer [5]. Recently, studies by
this lab localized a proinflammatory cytokine, macro-
phage migration inhibitory factor (MIF) in the urothe-
lium of experimental rats [6]. Chemical or
lipopolysaccharide-induced cystitis was found to induce
increases in the protein levels and mRNA expression of
MIF in nervous system structures innervating the bladder
suggesting a role for MIF in bladder inflammation [7,8].
From these findings, we hypothesized that MIF may func-
tion similarly in the human bladder.
MIF is a ubiquitously expressed protein that is able to
manifest itself as a cytokine, hormone, or enzyme [9].
Consequently, it maintains a key regulatory role in
inflammation and both specific and nonspecific immu-
nity. As a proinflammatory cytokine, MIF counter-regu-
lates the effects of glucocorticoids and stimulates the
secretion of certain other cytokines such as tumor necrosis
factor (TNF)-α and interleukin (IL)-1β [10], thus assum-
ing a role in the pathogenesis of inflammatory, immune
diseases and cancer including septic shock [11], rheuma-
toid arthritis [12], Crohn's disease [13], and lung [14],
breast [15], and prostate [16,17] cancers.
In addition to its roles in inflammation and immunity,
MIF is suggested to be involved in tumor cell growth and
differentiation [18]. It has been reported that MIF mRNA
is over-expressed in both prostatic [16,17] and breast [15]
tumors. MIF has also been associated with the growth of
lymphoma cells, melanoma cells, and colon cancer cells
[18]. Treatment with anti-MIF immunoglobulin therapy
has been shown to possess anti-tumor activity [19].
Although MIF is associated with cancer angiogenesis, pro-
gression and metastasis the exact mechanism of this
cytokine's action is unknown, as a receptor has only
recently been identified as the cell surface form of the
invariant chain (CD74) [20]. CD74 regulates loading of
exogenous derived peptides onto major histocompatibil-
ity class II heterodimers, but a small portion of the total
cell CD74 content is expressed on cell surfaces [21]. Acti-
vation of cell surface CD74 requires interaction with
CD44, a major adhesion molecule expressed in most cell
types that has a strong affinity for hyaluronan (HA)
[22,23]. CD44's extracellular domain is cleaved by mem-
brane bound matrix metalloproteinases [24] and the
resulting soluble CD44 reported as the most dominant
form of CD44 expressed in tumors [25].
Currently, no information exists on the expression of MIF
in the human bladder or its association with bladder can-
cer. In an effort to identify new therapies for the treatment
of bladder cancer, the aims of the present study include
documentation of MIF synthesis and secretion by human
bladder cancer epithelial cells. An additional aim of this
study is determination of the effects of high molecular
weight HA (a linear glucosaminoglycan) known to inhibit
MIF [26], as well as anti-MIF antibody and MIF anti-sense
oligonucleotides on in vitro bladder cancer cell growth
and cytokine expression. Finally this study ascertains
whether MIF associates with CD74 or CD44 in bladder
cancer cells.
Methods
MIF in human bladder
Tissue microarray slides were obtained from the Coopera-
tive Human Tissue Network (CHTN, block 2002N1A) of
the National Cancer Institute, The National Institutes of
Health, Bethesda, MD and used for both immunohisto-
chemistry (IHC) and in situ hybridization to document
MIF location in human bladder tissue. MIF IHC was per-
formed as described previously [27]. Control slides were
not treated with primary antiserum. MIF biotinylated
probes for in situ were prepared by reverse transcription,
followed by amplification of a 254 base pair (bp) MIF
fragment [17]. T7 RNA polymerase promoters were
ligated to the PCR product (Ambion, Austin, TX) and sin-
gle stranded RNA oligonucleotide probes produced by in
vitro T7 transcription (Promega, Madison, WI) with incor-
poration of biotinylated-dUTP. Tissue arrays were hybrid-
ized overnight with 100 ng probe, washed at a final
stringency of 0.1 × SSC at 60°C for 30 min and probes
detected with avidin-peroxidase (ISH-B1, Sigma, St. Louis,
MO). Negative controls included hybridization with
sense-biotinylated probes and hybridization without
probe addition. A poly d(T) biotinylated probe was used
as a positive control. Slides were not counterstained.
Cell culture
HT-1376 cells (ATCC, Manassas, VA) were plated at 1.0 ×
105 cells per well overnight in DMEM supplemented with
5% FBS, then rendered quiescent by overnight incubation
in serum free medium. Media was exchanged for that with
no supplement or one of the following: sodium hyaluro-
nate (0–500 µg/ml; Healon®, Pharmacia & Upjohn,
Kalamazoo, MI), monoclonal anti-human MIF antibody
(0–500  µg/ml; MAB289, R&D Systems, Minneapolis,
MN) or anti-sense MIF mRNA (0–500 ng/ well). Controls
for antibody treatment included addition of non-specific
mouse monoclonal antibody (Sigma) and for anti-sense
treatment addition of MIF sense mRNA at the appropriate
concentrations.
Anti-sense MIF was prepared by reverse transcription of
total RNA collected from the HT-1376 cells, followed by
amplification of a 254 base pair (bp) MIF fragmentBMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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(nucleotides 67–321). T7 RNA polymerase promoters
were ligated to the PCR product (Lig-N-Scribe, Ambion,
Austin, TX) and single stranded RNA oligonucleotide
probes were produced from this template by in vitro tran-
scription (Promega, Madison, WI) were then alkaline
treated and neutralized to produce small random frag-
ments. Transfection of the cells was carried out using Lipo-
fectAMINE PLUS Reagent (Invitrogen, Carlsbad, CA).
Anti-sense (or sense) RNA was mixed with 10 µl of serum-
free DMEM and 1 µl of PLUS Reagent followed by 0.5 µl
of LipofectAMINE Reagent then diluted with 10 µl of
serum-free DMEM. 50 µl of serum-free DMEM/F12 was
added to each well, followed by 20 µl of transfection mix.
Plates incubated at 37°C and 5% CO2 for 3 h. Following
incubation, 70 µl of 1% serum DMEM was added to the
wells.
Proliferation was assessed using a colorimetric assay
(MTS, Promega). Upon media removal from the wells,
100 µl of DMEM containing 20 µl MTS was added. Cells
were incubated for 30 min, followed by measurement of
the absorbance of the formazon product at 490 nm. For
quantification, relative numbers of cells per well were
determined using a generated standard curve. The exact
cell counts were determined by direct counting and two-
fold dilutions of cells in 100 µl volumes of 105 to 102 cells
per well were attached for 8 h, then incubated with MTS
reagent for 30 min. The growth curve to estimate cell
counts was produced by plotting the OD 490 nm of the 30
min MTS incubation versus the exact cell number. Data
are expressed total cell numbers and are the treatment
group means (n = 6) from three separate experiments.
Protein analysis
Following 24 h exposure to the different treatments, cul-
ture media was collected and immediately frozen at -80°C
and cells lysed by the direct addition of 100 µl RIPA buffer
(150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS
and 50 mM Tris, pH 7.5) with protease inhibitors
(Sigma).
Cell lysate samples were tested for caspase-3 activity using
reaction buffer (20 mM HEPES pH 7.4 containing 100
mM NaCl, 10 mM DTT, 0.1% CHAPS, and 10% sucrose)
and 4 mM DEVD-pNA substrate (Sigma) followed by
incubation in the dark at 37°C for 2 h. Absorbance levels
were read at 405 nm.
Protein concentrations were determined by modified
Bradford assay (BioRad, Hercules, CA). Proteins (30 µg/
ml total) were separated by polyacrylamide gel electro-
phoresis [7] and transferred to PVDF for Western blot
analysis. CD44 and CD74 protein bands were visualized
using specific antibodies (Santa Cruz, Ann Arbor, MI).
The resultant protein bands were quantified by digital
imaging [7]. Data are expressed as integrated density val-
ues (IDV, band area times relative intensity) and are the
treatment group means of Western blot determinations
performed from three separate experiments.
Secreted and intracellular levels of MIF were quantified
using a sandwich ELISA [17]. Data are expressed as pg/105
cells and are the treatment group means from three sepa-
rate experiments.
Localization of MIF in human bladder Figure 1
Localization of MIF in human bladder – A) MIF IHC – MIF protein is localized to the urothelial cells with mostly cytoplasmic 
staining and some evidence of perinuclear localization. The apical surface of the urothelial cells exhibits intense immunostaining 
(arrows). B) MIF in situ hybridization – MIF mRNA is localized primarily to the urothelial cytoplasm.BMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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An array for secreted human cytokine proteins (Human
Cytokine Array V, RayBio, Norcross, GA) was used to
determine relative changes in secreted cytokines. Mem-
branes with immobilized antibodies were incubated for
14 h with either 1 ml of the control media (untreated,
non-specific IgG treated or sense- treated) or 1 ml of the
experimental media pooled from 12 wells, followed by
biotin-conjugated antibodies, then horseradish-peroxi-
dase (HRP)-conjugated streptavidin (0.2 µg/ml) (DuoSet,
R&D Systems) and detected by chemiluminescence (ECL
Plus, Amersham, Piscataway, NJ). Integrated density val-
ues were calculated for each spot (area times relative
intensity). Then positive control signals on each mem-
brane were used to normalize cytokine signal intensities
using SigmaScan Pro image-analysis software (Jandel Sci-
entific Software, San Raphael, CA). A two-fold change in
spot intensity from treated culture medium compared to
control culture medium was considered significant. For
each treatment, the array analysis was performed twice
using conditioned medium from two separate experi-
ments. The mean treatment control data are expressed as
a mean protein ratio ± the standard error, which were
determined by dividing the normalized integrated density
values of the cytokine spot from all of the control cultures
by the integrated density value of the positive control
(HRP) spot. The effect of treatment on cytokine secretion
was determined by dividing the cytokine spot normalized
integrated density value from the treatment culture by the
cytokine spot normalized integrated density value from
the control culture. Data are expressed as +, greater than 2
fold increase; -, greater than 2 fold decrease; (-) decreased
beyond detection.
Gene expression analysis
Total RNA was obtained from cells by the direct addition
of TRIzol Reagent (Invitrogen). 1 µg of extracted total
RNA was reverse transcribed (Promega) and MIF ampli-
fied by PCR using as described [27]. IL – 1β or TNF-α were
amplified as described [28]. Control conditions and
quantification of resultant PCR bands intensities were as
described [8]. Data are expressed as a ratio of target PCR
band area intensity divided by 18 S rRNA internal stand-
ard band area intensity.
Immunoprecipitation
The association of MIF with CD74 and CD44 in HT-1376
cells was ascertained by immunoprecipitation with either
anti-human CD74 or CD44 (3 µg/ml, Santa Cruz) using
Protein G agarose beads per the manufacturer's protocol
(Kirkegaard & Perry Laboratories, Gaithersburg, MD), fol-
lowed by detection on Western blots. All incubations were
performed at 4°C with continuous rocking. Cleared cell
lysates were incubated overnight with antibody and equil-
ibrated Protein G agarose beads (Kirkegaard & Perry Lab-
oratories, Gaithersburg, MD). Controls included
incubation of pre-cleared samples with nonspecific poly-
clonal IgG (Sigma) and samples without addition of anti-
body in the immunoprecipitation reaction.
Statistical analysis
Statistical analysis was performed using Prism statistical
analysis software version 4 (GraphPad Software). For
ELISA and MTS assays linear regression with interpolation
was used to determine either antigen concentration or cell
number, respectively. The results of all other experiments
were analyzed using unpaired two-tailed t test or analysis
Effect of treatments on HT-1376 cell proliferation Figure 2
Effect of treatments on HT-1376 cell proliferation. A) Dose 
response curve – Effect of varying concentrations of HA, 
anti-MIF antibody and MIF anti-sense on HT-1376 cell growth 
over 24 h period. Data are expressed as percentage of con-
trol for each condition. Control conditions: HA, DMEM plus 
1% BSA, anti-MIF antibody; non-specific mouse IgG1 at 50 
µg/ml; antisense, MIF sense RNA at 2 ng/ml. The first dose to 
produce a statistically significant decrease in cell proliferation 
is listed for each treatment (* p < 0.05; ** p <0.01) and was 
used as the minimal effective dose for subsequent experi-
ments. B) Minimal effective dose – Effect of minimal effective 
doses of HA, anti-MIF antibody and MIF anti-sense on HT-
1376 cells following 24 and 48 h treatment. All treatments 
resulted in a decrease cell proliferation at both time periods, 
with a greater effects observed after 48 hours. Data are 
expressed as cell number as measured by MTS assay (* – p < 
0.05, ** – p < 0.01)BMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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of variance (ANOVA). Data are reported as the mean val-
ues ± standard error of the means (SEM). Statistical signif-
icance was determined at values of p < 0.05.
Results
MIF localization in normal human bladder
MIF protein is readily detected within the normal human
urothelium (Fig. 1A). MIF protein was primarily localized
throughout the urothelial cytoplasm with some evidence
of perinuclear localization (Fig. 1A). In addition, there
was intense apical staining in the surface urothelial cells
(Fig. 1A, arrows). MIF in situ established that the urothe-
lium was the source of the detected MIF protein as MIF
mRNA was detected in the urothelial cytoplasm (Fig. 1B).
The in situ signal was variable, but detectable through the
full thickness of the urothelium.
Treatment effects on cell proliferation
Hyaluronan, anti-MIF or MIF antisense reduced HT-1376
cell proliferation in a dose-dependent manner (Fig 2A).
The first dose that resulted in a statistically significant
decrease in cell proliferation was determined the mini-
mum effective concentration to be used in subsequent
experiments. Minimum effective concentrations of all
treatments (hyaluronan, 100 µg/ml; monoclonal anti-
human MIF antibody, 50 µg/ml; anti-sense MIF mRNA,
200 ng/ml); resulted in a small but significant reduction
in cell numbers 24 h post-treatment and 48 h post-treat-
ment when compared to untreated control cells (Fig. 2B,
p < 0.01). This reduction in total cell numbers was not
attributable to apoptosis induction as no capsase-3 activ-
ity was detected in cell lysates from HA, anti-MIF antibody
or anti-sense treated cell cultures (data not shown). There
was no significant reduction in cell proliferation in non-
specific IgG (anti-human IgG1 antibody, 50 µg/ml) or
MIF-sense (sense MIF mRNA, 200 ng/ml) treated cells
indicating that the reduction in cell numbers was not due
to either non-specific antibody effects or the transfection
protocol, respectively (data not shown). HT-1376 cells
secrete large amounts of hyaluronidase and various pro-
teases [29], the effects of the various treatments on MIF
expression and cytokine production were examined at 24
h so as to limit potential confounds associated with
hyaluronan degradation and antibody proteolysis.
Treatment effects on MIF production by bladder cancer 
cells
HT-1376 cells constitutively secrete MIF at concentrations
comparable to those determined in prostate cancer cells
[27]. The secreted MIF amounts significantly declined
with all treatments with the greatest decrease seen with
anti-MIF treatment (Fig. 3A; p < 0.001).
It could be argued that anti-MIF treatment does not reduce
MIF secretion, but rather the resulting interaction between
secreted MIF and the exogenously added antibody results
in an inability to detect MIF in the culture medium by
ELISA. We performed Western blot analysis of culture
medium, since under reducing conditions MIF protein
should dissociate from anti-MIF IgG. Western blot analy-
sis revealed a single 12 kDa band corresponding to the
known molecular weight of MIF [30]. These results con-
firmed that the anti-MIF treatment inhibited MIF secre-
tion, as Western blot analysis detected little MIF protein in
cell culture medium after anti-MIF treatment (Fig. 3B, lane
3).
Concomitant with the decreased secreted MIF were
changes in the intracellular MIF content (Fig. 3C). HA
treatment resulted in a small but significant increase in the
intracellular MIF content (p < 0.05), while anti-MIF treat-
ment had no effect on intracellular MIF content and MIF
antisense treatment resulted in a decrease in total MIF
content, as would be expected (p < 0.05). MIF mRNA
amounts decreased significantly with all treatments when
compared to control cultures (Fig. 3D).
Treatment effects on TNF-α and IL-1β expression
MIF blockade has been shown to affect the production of
various proinflammatory cytokines [10]. RT-PCR analysis
was performed to determine whether the HA, anti-MIF
antibody and MIF-antisense altered the expression of
TNF-α and IL-1β mRNA in HT-1376 cells (Fig. 4). HA had
no effect on TNF-α mRNA, while anti-MIF antibody and
MIF anti-sense significantly decreased TNF- mRNA
amounts when compared to untreated cells (Fig. 4A). IL-
1β expression, on the other hand, was not affected by any
treatment (Fig. 4B).
Treatment effects on secreted cytokine
Treatments effects on the amounts of proinflammatory
cytokines detected in culture medium was studied using
protein arrays. The conditioned medium from all HT-
1376 controls (untreated, non-specific IgG and sense)
contained 65 out of the possible 79 cytokines on the
array. There was no difference in the protein ratios of the
65 secreted cytokines in the different controls (Table 1).
Secretion of 18 cytokines was downregulated by all three
treatments (>2-fold, Table 1). Significant among the
cytokines downregulated by all three treatments were the
CXC chemokines CXCL5 and CXCL1, previously shown
by others as induced by MIF resulting in increased small
lung cell tumor cell angiogenic activity (Table 1A, [31]).
Nine of the 18 cytokines downregulated by all three treat-
ments were CC chemokines (Table 1).
HA decreased the amounts of 27 of the secreted cytokines
with a complete loss of detectable TNF-α and MIF with no
effect on the secreted amounts of IL-1β. Anti-MIF anti-
body decreased the amounts of 55 of the secreted
α .BMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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cytokines with complete loss of TNF-α, IL-1β and MIF.
While, MIF anti-sense treatment resulted in a decrease in
61 of the secreted cytokines and reduction of secreted
TNF-α (4-fold) with complete loss of detectable secreted
MIF and IL-1β.
The secreted cytokine array identified two cytokines not
previously identified as secreted by bladder cancer cells
(as determined by PubMED search); MDC (macrophage
derived chemokine, CCL22) and fractalkine (CX3CL1).
Treatment effects on CD 74 (MIF receptor) and CD 44 (HA 
receptor)
Based upon recent experiments by other groups [20], the
interaction of MIF with CD74 and CD44 are key to MIF
signal transduction. Immunoprecipitation assays were
performed to ascertain whether MIF interacts with CD74
or CD44 in HT-1376 cells. MIF was detected by Western
blotting of protein complexes precipitated from HT-1376
cell lysates by CD74 antibody (Fig. 5A, lane 1) and CD44
antibody (Fig. 5A, lane 2). The MIF amounts associated
with CD74 were much less than that associated with
CD44. This likely reflects the relative abundance of these
Effect of treatments on MIF secretion, intracellular content and gene expression Figure 3
Effect of treatments on MIF secretion, intracellular content and gene expression. A. MIF secretion – Conditioned medium fol-
lowing 24 h growth was assayed for MIF content by ELISA. Data are expressed as culture medium MIF concentration in pg per 
105 cells. All treatments decreased MIF in the culture media. B. Western blot of anti-MIF treated conditioned medium following 
24 h treatment- 12 kDa MIF band is present in all samples. Lane 1, DMEM 1% BSA; Lane 2, non-specific mouse IgG1; Lane 3, 
anti-MIF antibody treatment. C. Intracellular MIF content – Changes in intracellular MIF 24 h post treatment. Data are 
expressed as cleared cell lysate MIF concentration in pg per 105 cells. Note that HA treatment increased, while MIF antisense 
treatment decrease the concentration of MIF in the cell lysates. Anti-MIF treatment did not produce a significant effect. D. MIF 
gene expression -MIF mRNA content was quantified in cells following 24 h and the indicated treatment. Data are expressed as 
a relative intensity ratio. PCR band intensity was determined from the formula, total intensity = area × average intensity. The 
relative intensity ratio is determined from the total intensity of gene specific PCR product band divided by the 18 S rRNA band 
intensity (internal standard). All treatments resulted in a decrease in MIF mRNA with the greatest effects seen following MIF 
anti-sense treatment. (* – p < 0.05, ** – p < 0.01, *** – p < 0.001).
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two proteins in HT-1376 cells, which is demonstrated in
the Western blots of untreated cultures (Fig. 5C and 5E,
lane 1). Interaction of CD74 with CD44 was demon-
strated by immunoprecipitation with CD44 antibody
with detection of CD74 on Western blots (Fig. 5A, lane 5).
Antigen specific bands were absent in Western blots using
non-specific antibody or with no antibody in the immu-
noprecipitation (Fig. 5A, lane 3, 4). Confirmation of the
production of CD74 by HT-1376 cells was accomplished
by Western blots (Fig. 5C, lane 1). In all instances, treat-
ment resulted in a significant increase in CD74 protein
(Fig. 5C, lanes 2 – 4 respectively).
CD44 production by HT-1376 cells was confirmed by
Western blot analysis (Fig. 5E, lane 1). The effect of treat-
ments on CD44 protein concentrations was determined
by Western blot analysis (Fig. 5D,5E). A major band at
approximately 60 kDa was identified, which corresponds
to the known size of soluble CD44 [24]. Soluble CD44
amounts were significantly decreased by HA and anti-MIF
antibody treatment (p < 0.001, Fig. 5E, lane 2 and 3
respectively), while the CD44 concentrations were not
affected by MIF anti-sense treatments (Fig. 5D lane 4).
Discussion
MIF is a unique proinflammatory cytokine, found pre-
formed in various tissues, which plays a critical role in
immune response and inflammation [10]. Over the past
several years evidence has accumulated supporting a role
for MIF in various disease pathologies. In particular, sig-
nificant experimental data have emerged linking MIF to
the development and aggressiveness of adenocarcinoma
[32]. Increased MIF expression has been associated with a
wide variety of tumor cell types including breast [33],
prostate [16,17], lung [34], colon [35], liver [36], and
glioblastoma [37]. Prior studies in this laboratory deter-
mined that MIF is located in the rat bladder [6]. Here we
report for the first time on the presence of MIF in the
human urothelium and MIF synthesis and secretion by
HT-1376 human transitional cell carcinoma cells.
HA treatment significantly decreased secreted MIF
amounts. In this instance, the interference with MIF secre-
tion is evidenced by the significant increase in intracellu-
lar MIF content along with the attenuation of MIF gene
expression. Anti-MIF antibody treatment resulted in the
maximum suppression of MIF secretion (90.1%). Con-
versely, MIF anti-sense treatment decreased both the intra-
cellular MIF content and the amount of secreted MIF,
suggesting that MIF anti-sense treatment interfered with
MIF synthesis.
Endogenous MIF secretion may activate autocrine and/or
paracrine regulatory loops that enhance or sustain cancer
cell growth [38]. While, the precise molecular mechanism
behind MIF's function in tumorigenesis and metastasis is
unknown numerous studies have determined that reduc-
tion in tumor MIF results in reduced cell proliferation
[39], apoptosis induction [40], and reduction in the secre-
tion of other growth factors and cytokines [41]. In accord-
ance with previous findings, all the treatments used in the
present study were found to have a suppressive effect on
HT-1376 cell proliferation.
MIF is suggested to function as a regulator of pro-inflam-
matory gene and cytokine expression, and thus, altera-
tions in MIF activity are expected to affect the expression
and secretion of other proinflammatory molecules and
Effect of MIF Inhibition on TNF-α and IL-1β gene expression Figure 4
Effect of MIF Inhibition on TNF-α and IL-1β gene expression 
– A. TNF-α expression – TNF-α mRNA content was quanti-
fied in cells following 24 h with the indicated treatment. Anti-
MIF and MIF antisense treatments decreased the levels of 
TNF-alpha mRNA. HA treatment, however, was not effec-
tive. B. IL-1β expression – IL-1β mRNA content was quanti-
fied in cells following 24 h with the indicated treatment. No 
significant difference in IL-1β expression was seen with any of 
the treatments. In both A and B the data is expressed as a 
relative intensity ratio. PCR band intensity was determined 
from the formula, total intensity = area × average intensity. 
The relative intensity ratio is determined from the total 
intensity of gene specific PCR product band divided by the 18 
S rRNA band intensity (internal standard), (* – p < 0.05, ** – 
p < 0.01).
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Table 1: Secreted cytokine array. Secreted proinflammatory cytokines down-regulated by HA, anti-MIF antibody and MIF anti-sense. 
Integrated density values (IDV, average intensity times total area) were determined for each individual cytokine dot. Individual cytokine 
dot intensities were normalized to HRP-positive controls on each membrane. Mean control data for each cytokine spot are expressed 
as protein ratios (cytokine specific band integrated density value divided by HRP-positive control integrated density value). Treatment 
data are expressed as +, greater than 2 fold increase in secretion compared with control cytokine spot; -, greater than 2 fold decrease 
in secretion compared with control cytokine spot; (-), decreased beyond detection.
Cytokine Family
Control (Mean 
Protein Ratio)
HA α-MIF AS
Chemokine CC
CCL2 1.27 ± 0.04 - (-)
CCL4 0.30 ± 0.02 - (-) (-)
CCL5 0.18 ± 0.01 - (-) (-)
CCL11 0.11 ± 0.01 (-) (-) (-)
CCL15 0.41 ± 0.04 (-) (-) -
CCL17 0.12 ± 0.01 - (-) (-)
CCL18 1.97 ± 0.07 - (-) -
CCL20 0.69 ± 0.04 (-) -
CCL22 0.19 ± 0.02 - (-) -
CCL23 0.12 ± 0.01 (-) (-) (-)
CCL24 0.14 ± 0.01 - (-) -
CCL26 0.20 ± 0.01 (-) (-) (-)
CXC Chemokine
CXCL1 0.16 ± 0.02 - - (-)
CXCL2 0.15 ± 0.02 - - (-)
CXCL5 0.19 ± 0.02 - (-) (-)
CXCL6 0.26 ± 0.03 - - -
CXCL7 1.56 ± 0.03 - (-) -
CXCL8 0.32 ± 0.02 - -
CXCL9 0.16 ± 0.01 - (-) -
CXCl10 1.60 ± 0.17 - - -
CXCL12 0.15 ± 0.01 - (-) -
CXCL13 0.34 ± 0.02 - (-) -
CXC3C Chemokine
CX3CL1 0.19 ± 0.01 - (-)
Cytokines
Leptin 0.19 ± 0.02 - (-) (-)
LIF 3.20 ± 0.04 -
MIF 0.64 ± 0.04 (-) (-) (-)
OSM 0.20 ± 0.02 - (-) (-)
Interferon
INF-γ 0.17 ± 0.02 - (-) (-)
Neurotropins
BDNF 1.10 ± 0.05 - -
GDNF 1.30 ± 0.07 -
NT-3 2.00 ± 0.11 - (-)
NT-4 0.79 ± 0.04 - (-) -
Enzymes TIMP-1 2.54 ± 0.11 -
TIMP-2 5.29 ± 0.29 - +
Growth Factors
Ang-1 0.20 ± 0.02 (-) (-)
EGF 0.17 ± 0.03 - (-) -
FGF-4 0.24 ± 0.03 - (-) (-)
FGF-6 0.18 ± 0.01 - (-) -
FGF-9 0.81 ± 0.05 -
HGF 0.12 ± 0.02 - (-) (-)
MCSF 0.15 ± 0.02 - (-) (-)
PGIF 0.64 ± 0.05 - (-) -
Inhibin 0.17 ± 0.02 - (-) (-)
TGF β-2 3.20 ± 0.03 -
TGF β-3 0.77 ± 0.02 - (-) (-)BMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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cytokines [41]. The role of MIF in stimulating the produc-
tion of additional cytokines, including TNF-α, IL-1β,
among others has been previously documented [41,42].
MIF's exerts an upstream effect on TNF-α production [43].
Interestingly, the present study identified MIF blockade as
a key means to reduce the production of various proin-
flammatory and growth promoting cytokines and growth
factors by bladder tumor cells. All examined treatments
significantly altered the secretion of a wide range of
cytokines. In particular anti-MIF antibody and MIF anti-
sense treatments both abolished the secretion of TNF-α
and IL-1β. The decreased gene expression of TNF-α and
the altered cytokine secretion patterns lend further evi-
dence for MIF's role as a modulator of cytokine
production.
The observed reduction in cytokine production by MIF
blockade raises further questions about the physiological
relationship between MIF and other cytokines and the
possible importance of MIF interaction with HT-1376
cells. Recently CD74 was established as a MIF cell surface
receptor [20]. CD74, also known as the invariant chain
acts as a chaperone for major histocompatibility class
(MHC) II proteins [44]. CD74 plays a critical role in this
process by influencing both the expression and peptide
loading of MHC II molecules for antigen presentation.
Previously other investigators determined that greater
than constitutive amounts of recombinant MIF downreg-
ulated concentrations of CD74's intracellular ligand,
MHC II [45]. In the present studies we establish that HT-
1376 cells produce the MIF receptor and that its expres-
sion is upregulated when its extracellular ligand (MIF)
concentration is reduced. These findings support the
hypothesis that MIF modulates CD74 and MHC II
expression.
Recently it has been established that activated CD74 acts
as a signaling molecule by nuclear activation of NF-κβ
[46]. However, the intracellular portion of CD74 does not
contain domains predicted to activate downstream signal-
ing molecules. Of note, studies have suggested that
CD74's interaction with CD44 results in cellular activa-
tion [22,23]. HA binds the pleiomorphic cell surface mol-
ecule CD44, which functions in cell proliferation and
adhesion [47]. Recent studies indicate high molecular
weight HA binding to CD44 hinders its cleavage, thus
interrupting CD44 induced angiogenesis and tumor pro-
motion [48]. Membrane associated metalloproteinases
Hormone-like protein
IGF-1 0.14 ± 0.01 (-) (-) (-)
IGFBP-1 2.40 ± 0.10 -
IGFBP-2 1.40 ± 0.06 - -
IGFBP-3 2.50 ± 0.12 - (-)
IGFBP-4 0.11 ± 0.01 - (-) -
TP-3 0.13 ± 0.01 - (-) (-)
Interleukins
IL-1α 0.20 ± 0.01 - (-) (-)
IL-1β 0.14 ± 0.02 - (-) (-)
IL-2 0.14 ± 0.04 - (-) (-)
IL-12 0.16 ± 0.01 - (-) (-)
IL-15 0.10 ± 0.09 - (-) (-)
IL-16 0.27 ± 0.04 - (-) -
PDGF Superfamily
PDGF-B 0.17 ± 0.02 - (-) (-)
P1GF 0.59 ± 0.04 - (-) -
VEGF 3.20 ± 0.48 - + -
TNF Superfamily
TNFSF14 0.19 ± 0.01 - - (-)
TNFSF2 0.13 ± 0.02 (-) (-) -
TNFRSF11B 4.40 ± 0.04 -
CD Ligands
Fit-3 0.07 ± 0.01 - - (-)
Table 1: Secreted cytokine array. Secreted proinflammatory cytokines down-regulated by HA, anti-MIF antibody and MIF anti-sense. 
Integrated density values (IDV, average intensity times total area) were determined for each individual cytokine dot. Individual cytokine 
dot intensities were normalized to HRP-positive controls on each membrane. Mean control data for each cytokine spot are expressed 
as protein ratios (cytokine specific band integrated density value divided by HRP-positive control integrated density value). Treatment 
data are expressed as +, greater than 2 fold increase in secretion compared with control cytokine spot; -, greater than 2 fold decrease 
in secretion compared with control cytokine spot; (-), decreased beyond detection. (Continued)BMC Cancer 2004, 4:34 http://www.biomedcentral.com/1471-2407/4/34
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Effect of treatment on CD74 and CD44 proteins Figure 5
Effect of treatment on CD74 and CD44 proteins A. MIF pull down experiment – Cell lysates from 24 h control cultures were 
immunoprecipitated with CD74 antibody (lane 1) or CD44 antibody (lane 2,5) and the protein G binding protein complexes 
separated by polyacrylamide gel electrophoresis, followed by Western blotting using polyclonal anti-MIF or CD74 antibody. 
Lane 1, CD74 antibody; lane 2, CD44 antibody; lane 3, non-specific antibody; lane 4, no antibody added; lane 5, CD44 antibody. 
B. CD 74 Western blot analysis – Proteins in cell lysates from 24 h cultures treated with indicated reagents were separated by 
polyacrylamide gel electrophoresis, followed by Western blotting using polyclonal anti-CD74 antibody. Bands were quantified 
by digital imaging and are expressed as integrated density values (band area × relative intensity) and are presented as the mean 
± SEM of three separate experiments of quadruplicate cultures. All treatments increased the levels of CD74 in the cell lysates. 
C. CD 74 Western blot – Proteins in cell lysates from 24 h cultures treated with indicated reagents were separated by polyacr-
ylamide gel electrophoresis, followed by Western blotting using polyclonal anti-CD74 antibody. Blot is representative of those 
from three separate experiments. D. CD 44 Western blot analysis – Proteins in cell lysates from 24 h cultures treated with 
indicated reagents were separated by polyacrylamide gel electrophoresis, followed by Western blotting using polyclonal anti-
CD44 antibody. Bands were quantified by digital imaging and are expressed as integrated density values (band area × relative 
intensity) and are presented as the mean ± SEM of three separate experiments of quadruplicate cultures. HA and anti-MIF 
treatments significantly decreased the levels of CD44 in cell lysates. MIF antisense had no effect. E. CD 44 Western blot – Pro-
teins in cell lysates from 24 h cultures treated with indicated reagents were separated by polyacrylamide gel electrophoresis, 
followed by Western blotting using polyclonal anti-CD44 antibody. Blot is representative of those from three separate experi-
ments.(** – p < 0.01, *** – p < 0.001).
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cleave the extracellular domain of CD44 thus providing
changes in cell adhesion to the extracellular matrix, which
results in increased tumor cell migration [49]. In noncan-
cerous cells the intracellular domain of intact CD44 binds
to merlin resulting in a growth inhibitory signal [50]. It is
suggested that CD44 functions in MIF signal transduction
in some cells via horizontal recruitment of the protein
into the MIF-CD74 complex [20]. From the present study
it appears that although high molecular weight HA, which
interferes with CD44 function, reduces MIF secretion and
expression, this is still not sufficient to completely abro-
gate cell proliferation and cytokine secretion.
We developed a tentative model of MIF- CD44- CD74
interaction. Based upon our current model CD74 is the
rate-limiting member of MIF signal transduction complex
as it is found in rather low concentrations in HT-1376
cells when compared to CD44 or MIF. In HT-1376 cells
large quantities of MIF are constitutively synthesized and
secreted, which interact with soluble CD44. The soluble
CD44-MIF complex interacts with CD74 to induce activa-
tion of cytokine production and cell proliferation presum-
ably through ERK1/2 [51]. Treatment of HT-1376 cells
with high molecular weight HA blocks cleavage of CD44
resulting in decline in cell proliferation and cytokine pro-
duction. Anti-MIF antibody prevents interaction of MIF
with soluble CD44 again blocking MIF signal transduc-
tion. MIF anti-sense treatment results in inadequate MIF
amounts to interact with soluble CD44, which also results
in reduced cell proliferation and cytokine production.
Conclusions
In summary, the present study localized MIF within
human bladder tissue and identifies MIF synthesis and
secretion by human transitional cell carcinoma cells. The
results reported here, point towards MIF inhibition as a
directed therapeutic intervention in bladder cancer. Intra-
vesical instillation of HA, anti-MIF antibodies, and MIF
anti-sense presents as new potential therapies for bladder
cancer treatment. Pharmacological interference of the
hypothetical MIF-CD44-CD74 complex may offer a new
approach to treating bladder cancer.
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